Advertisement
Advertisement
U.S. markets open in 5 hours 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tryp Therapeutics Inc. (TRYPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1722-0.0182 (-9.56%)
At close: 01:44PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1904
Open0.1760
BidN/A x N/A
AskN/A x N/A
Day's Range0.1650 - 0.1932
52 Week Range0.1530 - 1.0400
Volume73,924
Avg. Volume76,044
Market Cap11.48M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1270
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TRYPF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TRYP THERAPEUTICS INC
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • PR Newswire

    Tryp Therapeutics to Participate in Healthcare Conferences in January 2022

    Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase.

  • PR Newswire

    Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder

    Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company's ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.

  • PR Newswire

    Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia

    Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") application is complete and that the Company may proceed with its clinical study in fibromyalgia.

Advertisement
Advertisement